Pharmaceutical giant AstraZeneca is betting on AI. The company has just signed a deal worth up to $555 million with U.S.-based startup Algen Biotechnologies. The partnership aims to advance therapies that combine gene editing with artificial intelligence.
AstraZeneca announced that it has joined forces with Algen Biotechnologies, signing an agreement that could reach a total value of $555 million. The British-Swedish biopharmaceutical company will pay $35 million upfront to accelerate Algen Biotechnologies’ research and development, with the remaining amount (over $500 million) to be paid once the startup achieves certain milestones — which have not yet been disclosed.
What exactly does AstraZeneca hope to achieve through such a large investment in a biotech startup? Primarily, a potential revolution in treating rare diseases by targeting their root causes through genetic modification. Algen will focus on gene therapies — commonly referred to as “gene editing.”
By leveraging artificial intelligence, Algen’s technology is designed to directly “target” the source of a disease rather than merely treating its symptoms. This approach could enable the precise insertion of genes into the appropriate cells within a patient’s body.
The collaboration appears to be mutually beneficial. It combines the “classic” strengths of a global pharmaceutical corporation with the cutting-edge innovation of Algen Biotechnologies, which in turn gains significant funding. Algen will contribute its latest AI-powered technologies, while AstraZeneca will provide support in costly clinical trials and, if successful, help navigate regulatory approval (from agencies such as the FDA) and bring new therapies to market.
If AstraZeneca and Algen Biotechnologies achieve even partial success in developing gene therapies, it could send a strong signal to the rest of the pharmaceutical industry and investors that it’s time to get serious about AI-powered biotech projects.